AbbVie Inc.
ABBV · NYSE
ABBV · NYSE
The consensus is Buy across 22 analysts. The supplied target figures are a $310 low, $288 mean and $310 high; the mean is below the stated low, so these figures cannot establish a coherent target cluster or spread. The evidence does not identify the most or least bullish analyst, or provide a dated rating or target revision during the past week, so revision direction is unavailable. The substantive debate in the coverage is whether Skyrizi- and Rinvoq-led immunology growth and neuroscience momentum, alongside Q3 beats and raised FY2026 adjusted EPS guidance, outweigh rising expenses, declining estimates and intensifying competition flagged before the report. No named analyst is tied to either side of that debate.
| Firm | Analyst | Rating | Price Target | Upside | Date | Source |
|---|---|---|---|---|---|---|
| Morgan Stanley | — | $310 | +8.7% | Oct 7, 2026 | Open the report this row came from | |
| Barclays PLC | — | $300 | +5.1% | Jul 29, 2026 |
| Barclays PLC | — | $300 | +5.1% | Jul 29, 2026 | Open the report this row came from |
| Wolfe Research | — | — | — | Jan 8, 2026 | Open the report this row came from |
| HSBC | — | $265 | -7.1% | Dec 10, 2025 | Open the report this row came from |
| HSBC | — | $265 | -7.1% | Dec 10, 2025 | Open the report this row came from |
| HSBC | — | $265 | -7.1% | Dec 10, 2025 | Open the report this row came from |
